External broker reports(aggregated public sources), Canaccord Genuity

Canaccord Genuity

External broker reports(aggregated public sources)

Canaccord Genuity Group Inc. is a leading independent investment bank with operations in North America, UK & Europe and Asia-Pacific. Canaccord Genuity Group Inc. is a leading independent, full-service financial services firm. Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

Acusensus Limited provides traffic management solutions. The Company offers road safety and traffic enforcement solutions to address road safety challenges. Acusensus serves customers worldwide.

<div><div><div><div><ul style="list-style-type: disc;"><li><p>ACE held its AGM and released a trading update highlighting ongoing momentum in business performance with the company is tracking ahead of market expectations for FY25.</p></li><li><p>FY25TD revenue of $19.2m (+19% pcp, CGe FY25E revg. +14% to $57m), gross profit of $9.2m (+35% pcp, 48% margin, CGe 45% margin), and adj. EBITDA of $2.8m (+35% pcp, representing an EBITDA margin of 15%, CGe 11%).</p></li><li><p>Observing its trend through 1H25TD highlights strong revenue acceleration in October to +26% pcp, against its 1Q25 revg of +17% pcp, coupled with ongoing sales of its higher-margin products (FT25TD incremental gross profit margin 78%) driving operating leverage/accelerated investment.</p></li></ul></div></div></div></div><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

ACE held its AGM and released a trading update highlighting ongoing momentum in business performance with the company is tracking ahead of market expectations for FY25.FY25TD revenue of $19.2m (+19% pcp, CGe FY25E revg. +14% to $57m), gross profit of $9.2m (+35% pcp, 48% margin, CGe 45% margin), and adj. EBITDA of $2.8m (+35% pcp, representing an EBITDA margin of 15%, CGe 11%).Observing its trend through 1H25TD highlights strong revenue acceleration in October to +26% pcp, against its 1Q25 revg of +17% pcp, coupled with ongoing sales of its higher-margin products (FT25TD incremental gross profit margin 78%) driving operating leverage/accelerated investment.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Acusensus Ltd - Scale Building; Growth Accelerates Through FY25

Laramide Resources Ltd. is a mineral resource company. The Company specializes in the acquisition, discovery and development of uranium projects. Laramide's current main focus is the Westmoreland Uranium Project in Queensland, Australia.

<ul><li>Laramide Resources (LAM-ASX) maintains five global uranium assets including two 100%- owned flagship projects in Crownpoint-Churchrock (New Mexico) and Westmoreland (Queensland).</li><li>Its resource base stands at an impressive 117Mlb.</li><li>With one final permit required for the Churchrock project, we believe LAM could provide much needed near-term supply to the US market. </li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Laramide Resources (LAM-ASX) maintains five global uranium assets including two 100%- owned flagship projects in Crownpoint-Churchrock (New Mexico) and Westmoreland (Queensland).Its resource base stands at an impressive 117Mlb.With one final permit required for the Churchrock project, we believe LAM could provide much needed near-term supply to the US market. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Laramide Resources Ltd - US Uranium Leverage with an Australian Kicker

Bannerman Resources Ltd. explores for uranium in Australia and Africa.

<ul><li>BMN has provided an update for its Etango project, highlighting the completion of FEED and Control Budget Estimates (June), early works for the construction of the water supply and site access (July) and ongoing progress with contracts/awards.</li><li>Importantly, the bulk earthworks contract has been awarded and is targeted as a 24-month contract, placing it in line with the company's critical path schedule.</li><li>Included within the update BMN has expanded its projected window for FID and is targeting a positive decision in 2025.</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

BMN has provided an update for its Etango project, highlighting the completion of FEED and Control Budget Estimates (June), early works for the construction of the water supply and site access (July) and ongoing progress with contracts/awards.Importantly, the bulk earthworks contract has been awarded and is targeted as a 24-month contract, placing it in line with the company's critical path schedule.Included within the update BMN has expanded its projected window for FID and is targeting a positive decision in 2025.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Bannerman Energy Ltd - Etango Project Update

Pyc Therapeutics Limited operates as a pharmaceutical company. The Company develops drugs and medicine for various types of diseases. Pyc Therapeutics serves customers in Australia.

<div><ul><li>This week, there were two international licensing deals in the RNA editing space by big pharma giant Novo Nordisk.</li><li>While details on specific terms were not released, we view activity in the sector as good for PYC and biotech in general, noting big pharma willingness to take on earlier stage risk and increased attention to the RNA space as a preferred sub-segment of gene editing.</li><li>Recall, recent clinical updates from its most advanced program, RP11 (blinding eye disease) demonstrated VP-001 had a notable (albeit early) positive effect on visual sensitivity, which was a key focus on the conference call.</li></ul></div><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

This week, there were two international licensing deals in the RNA editing space by big pharma giant Novo Nordisk.While details on specific terms were not released, we view activity in the sector as good for PYC and biotech in general, noting big pharma willingness to take on earlier stage risk and increased attention to the RNA space as a preferred sub-segment of gene editing.Recall, recent clinical updates from its most advanced program, RP11 (blinding eye disease) demonstrated VP-001 had a notable (albeit early) positive effect on visual sensitivity, which was a key focus on the conference call.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

PYC Therapeutics Limited - The RNA Space Is Heating Up

<ul><li>PYC reported its FY24 result, in line with the quarterly released in July. R&amp;D spend for the year was in line at $56m noting the company is punching well above its weight<br>in terms of capital efficiency.</li><li>Recall PYC is a platform clinical stage gene therapy company, with proprietary technology aimed at addressing shortcomings associated with competitor programs.</li><li>Recent clinical updates from its most advanced program, RP11 (blinding eye disease) demonstrated VP-001 had a notable (albeit early) positive effect on visual sensitivity, which was a key focus on the conference call. </li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

PYC reported its FY24 result, in line with the quarterly released in July. R&amp;D spend for the year was in line at $56m noting the company is punching well above its weight in terms of capital efficiency.Recall PYC is a platform clinical stage gene therapy company, with proprietary technology aimed at addressing shortcomings associated with competitor programs.Recent clinical updates from its most advanced program, RP11 (blinding eye disease) demonstrated VP-001 had a notable (albeit early) positive effect on visual sensitivity, which was a key focus on the conference call. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

PYC Therapeutics Limited - FY24: Clear Line of Sight to Multiple Near-Term Potential Catalysts